Trial Profile

An Open-Label, First-In-Human Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PEC QT (Primary)
Indications Type 1 diabetes mellitus
Focus Adverse reactions; First in man
Sponsors CRISPR Therapeutics

Most Recent Events

23 Jun 2023 Status changed from active, no longer recruiting to completed.
21 Feb 2023 According to a CRISPR Therapeutics media release, dosing has been completed in this trial.
22 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Apr 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com